Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future
b"We discuss all that and more this week on \\u201cThe Readout LOUD,\\u201d STAT\\u2019s biotech podcast. First, we break down a significant setback for Bluebird Bio\\u2019s gene therapy program with some help from Akshay Sharma, a bone marrow transplant expert at St. Jude Children\\u2019s Research Hospital. Then, STAT's Kate Sheridan joins us to discuss her deep dive into Flagship Pioneering, the superlatively successful and frequently grandiose venture firm behind Moderna. Finally, we dig into what the future might hold for a post-Trump FDA, which remains without a permanent commissioner."